Quadra Logic Technologies Inc. said that it has filed in Japan formarketing approval of its Photofrin product for early-stagetreatment of lung, bladder, esophageal, gastric and cervicalcancers.
The submission was made on QLT's behalf by Lederle (Japan)Ltd., a joint venture between American Cyanamid Co andTakeda Chemical Industries Ltd. The filing contains efficacyand safety data from a study of 150 patients involved in PhaseII and Phase III clinical trials in Japan.
"The new drug submission represents an important expansionin the potential market for Photofrin," said William J. Foran,president and chief executive of Vancouver, British Columbia-based QLT.
(c) 1997 American Health Consultants. All rights reserved.